<DOC>
	<DOCNO>NCT02846428</DOCNO>
	<brief_summary>This study evaluate efficacy safety treatment oral capecitabine intravenous ( IV ) 5-fluorouracil ( 5-FU ) , combination epirubicin cyclophosphamide , prior surgery participant breast cancer . The participant receive 4 cycle neoadjuvant Capecitabine + Epirubicin + Cyclophosphamide ( CEX ) 5-FU + Epirubicin + Cyclophosphamide ( FEC 100 ) chemotherapy first treatment period ( Period 1 , Days 1-85 ) . After 4-6 week fourth cycle neoadjuvant chemotherapy ( Day 120 +/- 7 day ) , breast surgery regional lymph node dissection perform , follow within maximum 6 week second treatment period ( Period 2 , Days 1 85 ) participant study arm receive 4 cycle adjuvant docetaxel 100 milligram per meter square ( mg/m^2 ) IV infusion Day 1 21-day cycle . Upon completion second treatment period , participant enter post-treatment follow-up period last 5 year initial date participant randomization . During period participant evaluate year anniversary date randomization .</brief_summary>
	<brief_title>To Evaluate Efficacy Safety Capecitabine Prior Surgery Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Females unilateral , noninflammatory , nonmulticentric , nonmetastatic breast adenocarcinoma , consider candidate conservative management , whose diagnosis histologically confirm T23 , N01 , M0 accord tumornodesmetastasis ( TNM ) classification Clinically radiologically measurable lesion ( 2 dimension ) Eastern Cooperative Oncology Group ( ECOG ) performance Status le equal ( &lt; = ) 1 Females present brain metastasis neurological psychiatric disorder could interfere proper treatment compliance Previous radiotherapy , chemotherapy , hormonal therapy breast cancer Previous history malignancy last 5 year cutaneous basal cell carcinoma carcinoma situ uterine cervix Serious concomitant infection Pregnant lactating female</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>